Abstract
Sensitive to the massive diffusion of purported metabolic and cardiovascular positive effects of green tea and catechincontaining extracts, many consumers of cardiovascular drugs assume these products as a “natural” and presumably innocuous adjunctive way to increase their overall health. However, green tea may interfere with the oral bioavailability or activity of cardiovascular drugs by various mechanisms, potentially leading to reduced drug efficacy or increased drug toxicity. Available data about interactions between green tea and cardiovascular drugs in humans, updated in this review, are limited so far to warfarin, simvastatin and nadolol, and suggest that the average effects are mild to modest. Nevertheless, in cases of unexpected drug response or intolerance, it is warranted to consider a possible green tea-drug interaction, especially in people who assume large volumes of green tea and/or catechin-enriched products with the conviction that “more-is-better”.
Keywords: Green tea, herb-drug interaction, dietary-drug interaction, catechins, simvastatin, warfarin, nadolol, cardiovascular drugs.
Current Pharmaceutical Design
Title:Overview of Green Tea Interaction with Cardiovascular Drugs
Volume: 21 Issue: 9
Author(s): Jose P. Werba, Shingen Misaka, Monica G. Giroli, Shizuo Yamada, Viviana Cavalca, Keisuke Kawabe, Isabella Squellerio, Federica Laguzzi, Satomi Onoue, Fabrizio Veglia, Veronika Myasoedova, Kazuhiko Takeuchi, Eisuke Adachi, Naoki Inui, Elena Tremoli and Hiroshi Watanabe
Affiliation:
Keywords: Green tea, herb-drug interaction, dietary-drug interaction, catechins, simvastatin, warfarin, nadolol, cardiovascular drugs.
Abstract: Sensitive to the massive diffusion of purported metabolic and cardiovascular positive effects of green tea and catechincontaining extracts, many consumers of cardiovascular drugs assume these products as a “natural” and presumably innocuous adjunctive way to increase their overall health. However, green tea may interfere with the oral bioavailability or activity of cardiovascular drugs by various mechanisms, potentially leading to reduced drug efficacy or increased drug toxicity. Available data about interactions between green tea and cardiovascular drugs in humans, updated in this review, are limited so far to warfarin, simvastatin and nadolol, and suggest that the average effects are mild to modest. Nevertheless, in cases of unexpected drug response or intolerance, it is warranted to consider a possible green tea-drug interaction, especially in people who assume large volumes of green tea and/or catechin-enriched products with the conviction that “more-is-better”.
Export Options
About this article
Cite this article as:
Werba P. Jose, Misaka Shingen, Giroli G. Monica, Yamada Shizuo, Cavalca Viviana, Kawabe Keisuke, Squellerio Isabella, Laguzzi Federica, Onoue Satomi, Veglia Fabrizio, Myasoedova Veronika, Takeuchi Kazuhiko, Adachi Eisuke, Inui Naoki, Tremoli Elena and Watanabe Hiroshi, Overview of Green Tea Interaction with Cardiovascular Drugs, Current Pharmaceutical Design 2015; 21 (9) . https://dx.doi.org/10.2174/1381612820666141013135045
DOI https://dx.doi.org/10.2174/1381612820666141013135045 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Review on Experimental Methods for Diabetes Induction and Therapeutic Efficacy of Anti-diabetic Drug Loaded Nanoformulation
Current Drug Therapy Development and Clinical use of Prasugrel and Ticagrelor
Current Pharmaceutical Design The Na+/H+ Exchanger: A Target for Cardiac Therapeutic Intervention
Current Drug Targets - Cardiovascular & Hematological Disorders GLP-1, Incretin Mimetics and DPP 4 Inhibitors: New Ways in the Treatment of Type 2 Diabetes
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents The Right Ventricle: Biologic Insights and Response to Disease
Current Cardiology Reviews Xanthine Oxidase Inhibitors the Unappreciated Treatment for Heart Failure
Cardiovascular & Hematological Disorders-Drug Targets A Summary of Electrospun Nanofibers as Drug Delivery System: Drugs Loaded and Biopolymers Used as Matrices
Current Drug Delivery Beyond Cholinesterase Inhibition: Anti-Inflammatory Role and Pharmacological Profile of Current Drug Therapy for Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Lipoprotein (a) and Cardiovascular Risk: The Show Must go on
Current Medicinal Chemistry Lipids and Non-Cardiac Vascular Disease: A Lecture Overview
Current Vascular Pharmacology Current Approaches to Drug Discovery for Chagas Disease: Methodological Advances
Combinatorial Chemistry & High Throughput Screening Fatty Acids Recommendations: Controversies and Updates
Current Nutrition & Food Science AMPK - Activated Protein Kinase and its Role in Energy Metabolism of the Heart
Current Cardiology Reviews The Digenea Parasite Opisthorchis felineus: A Target for the Discovery and Development of Novel Drugs
Infectious Disorders - Drug Targets A New Risk Chart of Acute Myocardial Infarction in Men by an Innovative Algorithm: A Pilot Study
Current Pharmacogenomics and Personalized Medicine LPS In Patients With Left Ventricular Dysfunction Of Ischemic And Non-Ischemic Origin
Cardiovascular & Hematological Disorders-Drug Targets Cardiac (myo)fibroblast: Novel Strategies for its Targeting Following Myocardial Infarction
Current Pharmaceutical Design Anti-Cancer Activity of 2,4-Disubstituted Thiophene Derivatives: Dual Inhibitors of Lipoxygenase and Cyclooxygenase
Medicinal Chemistry Barriers to Optimising Prescribing and Deprescribing in Older Adults with Dementia: A Narrative Review
Current Clinical Pharmacology Editorial (Thematic Issue: Myokines and Exercise Training: More Shadows than Lights)
Current Pharmaceutical Design